Global Health Investment Fund (GHIF)
The Global Health Investment Fund (GHIF) is a $108 million social impact investment fund focused on financing the development of drugs, vaccines, diagnostics, and other health interventions aimed at combating diseases that disproportionately affect low- and middle-income countries. GHIF targets late-stage innovations addressing public health challenges, including malaria, pre-eclampsia, cholera, HIV, and river blindness, while particularly emphasizing infectious diseases and maternal/infant health issues that contribute to significant morbidity and mortality in resource-limited settings. The fund also invests in initiatives to enhance access to existing products, such as pediatric formulations and improved vaccine stability. With a limited investment horizon, GHIF seeks opportunities with a high likelihood of successful commercialization within two to three years, prioritizing products that demonstrate dual market potential and high-volume, low-margin characteristics. The fund utilizes various investment structures, including mezzanine and convertible debt, preferred equity, and project financing, with an average investment target of around $10 million per project. Each initiative must align with GHIF's social impact goals while showing potential for commercial success.
18 past transactions
Monod Bio
Seed Round in 2022
Monod Bio is a life sciences company headquartered in Seattle, Washington, specializing in the development of innovative biosensors for the detection of proteins, toxins, antibodies, and other analytes. Founded in 2021, the company leverages advances in computational protein engineering to create modular bio-sensing nanoswitches. These biosensors integrate binding, transduction, and amplification processes in a single step, allowing for rapid, sensitive, and cost-effective analytical assays. Monod Bio's technology aims to enhance the capabilities of the healthcare industry by providing advanced tools for biotechnology and medical applications.
Endpoint Health
Series A in 2022
Endpoint Health, Inc. is a precision immunology company focused on researching and developing therapies that enhance outcomes for patients with critical and immune-driven illnesses, including sepsis, acute respiratory distress syndrome, and COVID-19. Founded in 2018 and headquartered in Palo Alto, California, with additional offices in Detroit, Livonia, and Chicago, the company aims to overcome the limitations of traditional drug development by creating precision therapies tailored to individual patient needs. Utilizing its proprietary AI-powered platform, OMNAI, Endpoint Health identifies and matches high-potential therapies to patients most likely to benefit, ensuring personalized treatment that significantly improves health outcomes. The company is committed to delivering innovative solutions that address the complexities of autoimmune and inflammatory conditions.
Eyenuk
Venture Round in 2020
Eyenuk, Inc. is a medtech company that specializes in artificial intelligence-based retinal image analysis and disease detection technology. Founded in 2010 and headquartered in Woodland Hills, California, Eyenuk develops innovative solutions aimed at enhancing the screening process for various eye diseases. Its flagship product, the EyeArt AI Eye Screening System, is recognized for its autonomous detection of diabetic retinopathy, requiring no expert human grading or eye dilation. The company also offers EyeMark, which monitors retinopathy progression, and EyeApp, a mobile application facilitating diabetic retinopathy screening via smartphones. Additionally, Eyenuk provides EyeSeeAMD, a technology designed to identify age-related macular degeneration. Through its advanced solutions, Eyenuk aims to ensure timely diagnosis of life- and vision-threatening conditions, including glaucoma and cardiovascular risks, ultimately striving to screen every eye globally.
Alydia Health
Series C in 2020
Alydia Health, Inc. is a medical device company focused on addressing postpartum hemorrhage (PPH), a leading cause of maternal mortality. Founded in 2010 and based in Menlo Park, California, the company designs and manufactures the Jada System, a device that helps control excessive bleeding after childbirth by promoting normal uterine contractions. This innovative approach provides an effective solution without the need for pharmaceuticals, hysterectomy, or other surgical interventions, thereby improving treatment options for women experiencing PPH. Alydia Health aims to significantly enhance the management of postpartum hemorrhage, ultimately improving maternal health outcomes worldwide.
Plethy
Seed Round in 2019
Plethy is an InsurTech and HealthTech company focused on improving patient outcomes and financial returns for self-insured enterprises, insurance carriers, and health systems. The company has developed a care management platform designed to assist patients in managing their musculoskeletal care from home or while on the go. This platform integrates a wearable sensor and a software application that provides predictive analytics, allowing healthcare providers to enhance remote monitoring and tailor treatment plans effectively. By leveraging these insights, Plethy aims to facilitate better recovery processes and streamline claims closure, ultimately balancing quality of care with accessibility and cost efficiency.
Themis Bioscience
Series D in 2019
Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.
Alydia Health
Series B in 2018
Alydia Health, Inc. is a medical device company focused on addressing postpartum hemorrhage (PPH), a leading cause of maternal mortality. Founded in 2010 and based in Menlo Park, California, the company designs and manufactures the Jada System, a device that helps control excessive bleeding after childbirth by promoting normal uterine contractions. This innovative approach provides an effective solution without the need for pharmaceuticals, hysterectomy, or other surgical interventions, thereby improving treatment options for women experiencing PPH. Alydia Health aims to significantly enhance the management of postpartum hemorrhage, ultimately improving maternal health outcomes worldwide.
Univercells
Series B in 2018
Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.
Themis Bioscience
Series C in 2018
Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.
IanTech
Series C in 2017
IanTech is a medical device company based in Reno, Nevada, specializing in advanced micro-interventional technology for cataract surgery. The company has developed a pen-like device that utilizes nitinol micro-filament technology to perform energy-free endocapsular lens fragmentation. This innovative approach allows surgeons to efficiently manage challenging cataract cases through a minimally invasive clear cornea incision, ultimately improving surgical outcomes. IanTech aims to enhance surgical techniques and reduce the incidence of cataract-related blindness worldwide, addressing a significant global health issue. By focusing on smart and adaptable solutions, IanTech is committed to advancing cataract surgery and expanding access to effective treatments.
PATH
Venture Round in 2017
PATH is an international nonprofit organization that transforms global health through innovation. They take an entrepreneurial approach to developing and delivering high-impact, low-cost solutions, from lifesaving vaccines and devices to collaborative programs with communities. Through our work in more than 70 countries, PATH and our partners empower people to achieve their full potential.
Atomo Diagnostics
Venture Round in 2016
Atomo Diagnostics is an Australian company specializing in the research, design, development, and manufacture of medical devices for blood-based rapid testing, catering to both professional and consumer markets. Established in 2010 and headquartered in Leichhardt, Australia, the company offers its AtomoRapid RDT platforms, which are designed for a variety of blood-based lateral flow test assays. These devices are capable of screening for chronic conditions and detecting infectious diseases, including HIV. Atomo Diagnostics distinguishes itself by focusing on usability and user experience, addressing existing challenges in rapid diagnostic testing (RDT) through innovative design and patented features. This approach aims to enhance safety, accuracy, and reliability while minimizing user error. The company has a global presence, with operations in Europe, Asia, Africa, and Central and South America, and is led by an experienced management team dedicated to commercializing disruptive healthcare products.
Access Bio
Post in 2016
Access Bio, Inc. is a biopharmaceutical company based in Somerset, New Jersey, founded in 2002. The company specializes in the research, development, and manufacturing of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products aimed at the prevention and early diagnosis of infectious diseases. Access Bio's product portfolio features a range of rapid diagnostic tests, including CareStart G6PD, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM. Additionally, the company offers biosensor solutions such as the CareStart G6PD Biosensor, along with molecular diagnostic products like CareStart HPV and CareStart CAH. Through its innovative technologies, Access Bio contributes significantly to the healthcare industry by enhancing disease detection and management.
Atomo Diagnostics
Debt Financing in 2016
Atomo Diagnostics is an Australian company specializing in the research, design, development, and manufacture of medical devices for blood-based rapid testing, catering to both professional and consumer markets. Established in 2010 and headquartered in Leichhardt, Australia, the company offers its AtomoRapid RDT platforms, which are designed for a variety of blood-based lateral flow test assays. These devices are capable of screening for chronic conditions and detecting infectious diseases, including HIV. Atomo Diagnostics distinguishes itself by focusing on usability and user experience, addressing existing challenges in rapid diagnostic testing (RDT) through innovative design and patented features. This approach aims to enhance safety, accuracy, and reliability while minimizing user error. The company has a global presence, with operations in Europe, Asia, Africa, and Central and South America, and is led by an experienced management team dedicated to commercializing disruptive healthcare products.
Becton, Dickinson and Company
Post in 2015
Becton, Dickinson and Company is a medical technology company focused on advancing health through improved medical discovery, diagnostics, and care delivery. The company manufactures a range of medical devices and instrument systems, including surgical and diagnostic systems, patient monitoring tools, and infusion products. BD is recognized for its commitment to enhancing patient and healthcare worker safety, as well as providing technologies that support medical research and clinical laboratories. Through its innovative products, BD aims to improve outcomes for both doctors and patients.
Genedrive
Post in 2014
genedrive plc is a commercial stage medical devices company, targeting opportunities in infectious diseases, biosurveillance, and animal applications. Our Genedrive® system is positioned to offer lower cost, easy to use, point of need or clinic-based molecular diagnostic tests via a 'razor/razor blade' business model across an increasing range of applications. Genedrive® is rapidly reconfigurable for specific assays and is suitable for use outside a traditional hospital setting. The system analyses nucleic acids from fresh or stored samples to provide rapid diagnosis and decision making.
EuBiologics
Series B in 2014
EuBiologics Co., Ltd., established in 2010 and based in Seoul, South Korea, is a biopharmaceutical company specializing in the development and supply of vaccines for epidemic prevention and antibiotic resistance. Its product portfolio includes Euvchol, an oral cholera prevention vaccine, and CRM197, a diphtheria toxin mutant vaccine. The company also offers customized services for mammalian and microbial cell-derived biopharmaceuticals, supporting clients from cell line development to GMP production, along with regulatory support. Additionally, EuBiologics provides contract testing services, process and formulation development, and licensing consulting services, contributing to human health across various stages of life.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.